ImmunoGen Announces Webcast of Presentation at Deutsche Bank’s 43rd Annual Health Care Conference
A webcast of the presentation will be accessible live through the “Investors” section of the Company’s website, www.immunogen.com; a replay will be available in the same location for approximately two weeks.
ImmunoGen is a clinical-stage biotechnology company that develops targeted cancer therapeutics using its proprietary ADC technology. The Company’s lead product candidate, mirvetuximab soravtansine, is in the Phase 3 FORWARD I trial for FRα-positive platinum-resistant ovarian cancer, and is in the Phase 1b/2 FORWARD II trial in combination regimens for earlier-stage disease. ImmunoGen has three additional clinical-stage product candidates, two of which are being developed in collaboration with
Kadcyla® is a registered trademark of Genentech, a member of
Sarah Kiely, 781-895-0600
Courtney O’Konek, 781-895-0158
FTI Consulting, Inc.
Robert Stanislaro, 212-850-5657